Skip to main content
Full access
Images in Psychiatry
Published Online: 1 December 2008

The Dawn of Anxiolytics: Frank M. Berger, 1913–2008

The discovery that ushered in the era of tranquilizers and other anxiety medications was Frank Berger’s discovery of meprobamate. Frank Berger, M.D., was a microbiologist of Czech origin working in the United Kingdom during World War II. Shortly after Florey and colleagues purified penicillin, Berger was looking for a substance that would preserve penicillin by inhibiting penicillinase-producing bacteria. One of these substances, mephenesin (Myanesin) met this criterion. While performing toxicity studies, Berger noted that large doses of mephenesin produced tranquilization in laboratory animals. He published his findings in 1946 in the British Journal of Pharmacology (1) .
Figure 1.
Shortly after this discovery, Berger moved to the United States and worked at Carter Products (later Carter-Wallace), a small pharmaceutical company. There he continued working with mephenesin, investigating why it was metabolized rapidly. He and his co-workers found that mephenesin’s rapid deactivation by oxidation of its terminal hydroxy groups was best blocked by carbamates. They synthesized a few hundred carbamates. Meprobamate (2) seemed to be “the best one.” Several clinical trials with meprobamate were conducted, one by Berger himself. To convince hesitant executives about meprobamate’s properties, Berger produced a short documentary showing the drug’s effect on rhesus monkeys. The brand name “Miltown,” after a small village near New Brunswick, N.J., was selected (meprobamate was also later distributed as “Equanil”). Meprobamate became extremely popular during the 1950s and opened the market to other “tranquilizing” drugs (e.g., chlordiazepoxide). Meprobamate relieved anxiety, relaxed muscles, and induced mild euphoria and “inner peace.” Some even suggested that it should be added to drinking water so the masses would be less anxious. Thus, it is interesting that the Associated Press reported in March 2008 that traces of meprobamate were found in water supplies of Los Angeles and several other places. Only a few years after its introduction, it became obvious that meprobamate could be habit forming, its sudden withdrawal could be dangerous, and overdose could be lethal. Its use decreased, especially after the arrival of benzodiazepines, but it never totally faded away. Generic meprobamate is still available.
Frank Berger continued his research and development of carbamates (e.g., the pain reliever carisoprodol) and later returned to bacteriology and immunology.
Berger is an example of an alert observer and astute researcher from the golden era of serendipity in psychopharmacology research, along with R. Kuhn, J. Delay, P. Deniker, and others. Recently, Donald Klein (3) reminded us of “a seismic shift in psychiatry between 1950 and 1970,” the Age of Serendipitous Psychopharmacology Discoveries. During those times, lithium, chlorpromazine, iproniazid, meprobamate, chlordiazepoxide, haloperidol, and other psychotropic drugs were “discovered” mostly because of “chance observations of unexpected clinical benefits or as inadvertent outcomes of blind pharmaceutical searches” (3) .

Footnote

Address correspondence and reprint requests to Dr. Balon, UPC-Jefferson, 2751 East Jefferson #200, Detroit, MI 48207; [email protected] (e-mail). Photograph used by permission of Christine Berger. Image accepted May 2008 (doi: 10.1176/appi.ajp.2008.08040552). The author thanks Thomas Ban, M.D., for providing information about Frank Berger.

References

1.
Berger FM, Bradley W: The pharmacological properties of α:β-dihydroxy-γ-(2-methylphenoxy)-propane (Myanesin). Br J Pharmacol 1946; 1:265–272
2.
Berger FM: The pharmacological properties of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown), a new interneuronal blocking agent. J Pharmacol Exp Ther 1954; 112:413–423
3.
Klein DF: The loss of serendipity in psychopharmacology. JAMA 2008; 299:1063–1064

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1531
PubMed: 19047334

History

Published online: 1 December 2008
Published in print: December, 2008

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share